In humans, peripheral blood eosinophilia often occurs when immunotherapy with interleukin (IL)-2 [33, 34], IL-4 [35], granulocyte macrophage colony-stimulating factor [36], or tumor vaccine is performed [37]. The gene discussed is IL2; the disease is Increased total eosinophil count.